ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
36 announcements with these filters
Shukra Pharmaceuticals Ltd filed its Annual Secretarial Compliance Report for FY 2025-26. The auditor confirmed statutory compliance despite the company crossing specific regulatory thresholds.
Shukra Pharmaceuticals confirmed zero deviation in utilizing ₹3.95 Crore raised via convertible warrants. The funds support working capital, debt repayment, and capital expenditure.
Shukra Pharmaceuticals Ltd reported revenue from operations of ₹6.3 Cr (-52.6% YoY) and a net loss of ₹1.7 Cr for Q4 FY26.
Shukra Pharmaceuticals approved FY26 audited financial results and recommended a 1% final dividend. The board also allotted 17.35 lakh equity shares upon warrant conversion.
Shukra Pharmaceuticals Ltd clarified that it does not meet the SEBI criteria to be classified as a 'Large Corporate' as of April 2026. The company reported outstanding borrowings of ₹4.17 Crore as of the fiscal year-end.
Shukra Pharmaceuticals Ltd has scheduled a Board Meeting on May 07, 2026. The board will consider audited financial results for the quarter and year ended March 31, 2026, and recommend a final dividend for FY 2025-26.